SAVA - CASSAVA SCIENCES INC
IEX Last Trade
2.355
-27.945 -1,186.624%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:16:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$30.30
-27.95
-92.23%
Fundamental analysis
22%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
18%
Performance
5 Days
-0.43%
1 Month
-45.52%
3 Months
-92.32%
6 Months
-87.87%
1 Year
-91.57%
2 Year
-92.61%
Key data
Stock price
$2.36
DAY RANGE
$2.36 - $30.30
52 WEEK RANGE
$2.41 - $42.20
52 WEEK CHANGE
-$89.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Remi Barbier
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.
Recent news